Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Dow
Harvard Business School
Merck
Colorcon

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 210296


Email this page to a colleague

« Back to Dashboard

NDA 210296 describes BAFIERTAM, which is a drug marketed by Banner Life Sciences and is included in one NDA. It is available from one supplier. There are nineteen patents protecting this drug. Additional details are available on the BAFIERTAM profile page.

The generic ingredient in BAFIERTAM is monomethyl fumarate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the monomethyl fumarate profile page.
Summary for 210296
Tradename:BAFIERTAM
Applicant:Banner Life Sciences
Ingredient:monomethyl fumarate
Patents:19
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 210296
Generic Entry Date for 210296*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE, DELAYED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 210296
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BAFIERTAM monomethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 210296 NDA Banner Life Sciences LLC 69387-001 69387-001-01 120 CAPSULE in 1 BOTTLE (69387-001-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrength95MG
Approval Date:Apr 28, 2020TE:RLD:Yes
Patent:⤷  Sign up for a Free TrialPatent Expiration:Feb 27, 2035Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING MULTIPLE SCLEROSIS
Patent:⤷  Sign up for a Free TrialPatent Expiration:Feb 27, 2035Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Sign up for a Free TrialPatent Expiration:Feb 27, 2035Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING MULTIPLE SCLEROSIS

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
McKesson
Merck
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.